(MedPage Today) — CHICAGO — An oral targeted drug reduced the risk of disease progression or death by 35% compared with chemotherapy when given as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
